Advertisement
Advertisement
U.S. Markets open in 7 hrs
Advertisement
Advertisement
Advertisement
Advertisement

Instil Bio, Inc. (TIL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.6500-0.2300 (-4.71%)
At close: 04:00PM EDT
4.6500 0.00 (0.00%)
After hours: 04:30PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.8800
Open4.9400
Bid0.0000 x 1800
Ask0.0000 x 1400
Day's Range4.6400 - 5.0700
52 Week Range3.9000 - 23.4900
Volume242,666
Avg. Volume353,947
Market Cap599.511M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.5750
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.75
  • GlobeNewswire

    Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit

    DALLAS, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in an upcoming investor conference: Jefferies Cell and Genetic Medicine SummitCompany presentation and Q&A: Thursday, September 29, 2022 at 10:30 a.m. ET A live webcast, if recorded, of the presentati

  • GlobeNewswire

    Instil Bio to Present at Morgan Stanley Global Healthcare Conference

    DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in an upcoming investor conference: Morgan Stanley 20th Annual Global Healthcare ConferenceFireside Chat: Monday, September 12, 2022 at 2:50 p.m. ET A live webcast, if recorded, of each presentation c

  • GlobeNewswire

    Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

    DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer. Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently PACT Pharma

Advertisement
Advertisement